Hospital for Special Surgery, New York, New York.
Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
Sports Health. 2024 May-Jun;16(3):333-339. doi: 10.1177/19417381231168799. Epub 2023 Apr 25.
Treatment for idiopathic adhesive capsulitis of the shoulder remains controversial. Stages 1 to 2 reflect an inflammatory process supporting a rationale for intra-articular glenohumeral joint corticosteroid injection to treat synovial inflammation and prevent progression to capsular fibrosis.
We hypothesize that an intra-articular ultrasound-guided glenohumeral injection (USGI) of corticosteroid in patients diagnosed with Stage 1 or 2 idiopathic adhesive capsulitis will result in timely functional recovery and resolution of pain and stiffness.
Case series.
Level 4.
Patients with Stage 1 or 2 idiopathic adhesive capsulitis treated with an intra-articular corticosteroid injection were included. Patients were seen by a single physician and diagnosed using history and physical examination with careful attention to measurement of glenohumeral range of motion (ROM). A total of 61 patients met inclusion criteria. ROM measurements documented in the patient charts were recorded in forward flexion, abduction, internal rotation, and external rotation in neutral abduction. All ROM measurements were performed pre- and postinjection. All patients were treated with an USGI of local anesthetic and depomedrol. Recovery criteria were defined as forward flexion, abduction, and external rotation within 15° of the contralateral side and internal rotation within 3 spinous process levels of the contralateral side.
A total of 11 patients with Stage 1 and 50 patients with Stage 2 adhesive capsulitis comprised the final study cohort. Within the Stage 1 cohort, all 11 patients met recovery criteria for forward flexion and internal rotation (100%), 10 met recovery criteria for abduction (91%), and 8 met recovery criteria for external rotation (73%). Within the Stage 2 cohort, 31 patients met recovery criteria for forward flexion (62%), 30 met recovery criteria for abduction (60%), 36 met recovery criteria for internal rotation (72%), and 25 met recovery criteria for external rotation (50%). The difference in time to recovery in days was statistically significant in all ROM planes and was within 2 to 6 weeks for patients in Stage 1 and 7 to 10 weeks for Stage 2.
USGI for early adhesive capsulitis allows patients to recover ROM more rapidly if performed early after onset of pain and stiffness.
These results stress the importance of recognition of idiopathic adhesive capsulitis in its early stages and subsequent intervention with an intra-articular glenohumeral corticosteroid injection.
肩部特发性粘连性关节囊炎的治疗仍存在争议。1 期至 2 期反映了炎症过程,支持关节内盂肱关节皮质类固醇注射治疗滑膜炎症并防止囊纤维化进展的合理性。
我们假设在诊断为 1 期或 2 期特发性粘连性关节囊炎的患者中进行关节内超声引导下盂肱关节注射(USGI)皮质类固醇将导致及时的功能恢复以及疼痛和僵硬的缓解。
病例系列。
4 级。
纳入接受关节内皮质类固醇注射治疗的 1 期或 2 期特发性粘连性关节囊炎患者。由一名医生对患者进行检查,并通过病史和体格检查进行诊断,仔细注意盂肱关节活动范围(ROM)的测量。共有 61 名患者符合纳入标准。病历中记录的 ROM 测量值记录在向前弯曲、外展、内旋和中立外展的外旋中。所有 ROM 测量均在注射前和注射后进行。所有患者均接受局部麻醉和地塞米松的 USGI 治疗。恢复标准定义为对侧侧向前弯曲、外展和外旋的角度在 15°以内,对侧侧内旋的角度在 3 个棘突水平以内。
最终研究队列包括 11 例 1 期和 50 例 2 期粘连性关节囊炎患者。在 1 期队列中,所有 11 例患者的前屈和内旋恢复标准(100%)、10 例外展恢复标准(91%)和 8 例外旋恢复标准(73%)。在 2 期队列中,31 例患者的前屈恢复标准(62%)、30 例外展恢复标准(60%)、36 例内旋恢复标准(72%)和 25 例外旋恢复标准(50%)。在所有 ROM 平面上,恢复时间的差异具有统计学意义,1 期患者为 2 至 6 周,2 期患者为 7 至 10 周。
如果在疼痛和僵硬发作后早期进行 USGI,则可以使早期粘连性关节囊炎患者更快地恢复 ROM。
这些结果强调了在早期识别特发性粘连性关节囊炎并随后进行关节内盂肱关节皮质类固醇注射干预的重要性。